Michael Barbella, Managing Editor03.12.24
electroCore Inc. has received two new patents from the U.S. Patent and Trademark Office for its non-invasive vagus nerve stimulation (nVNS) technology.
U.S. Patent No. 11,850,056, “Devices and Methods for Remote Therapy and Patient Monitoring,” generally relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a patient's heart rate variability (HRV), and comparing the HRV with data related to therapy regimen parameters.
U.S. Patent No. 11,854,695, “Medical Devices for Treating Medical Conditions," covers a medical device that includes a signal generator for applying electrical impulses to the patient for a period of time (i.e., a single dose), wherein the device is configured to deactivate upon a first occurrence of a specific number of single doses being applied to the patient or a specific time elapsing after the first dose is applied.
electroCore Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation technology platform. Its focus is the commercialization of medical devices for managing and treating certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
U.S. Patent No. 11,850,056, “Devices and Methods for Remote Therapy and Patient Monitoring,” generally relates to systems and methods for treating medical conditions that include delivering an nVNS therapy regimen, detecting a patient's heart rate variability (HRV), and comparing the HRV with data related to therapy regimen parameters.
U.S. Patent No. 11,854,695, “Medical Devices for Treating Medical Conditions," covers a medical device that includes a signal generator for applying electrical impulses to the patient for a period of time (i.e., a single dose), wherein the device is configured to deactivate upon a first occurrence of a specific number of single doses being applied to the patient or a specific time elapsing after the first dose is applied.
electroCore Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation technology platform. Its focus is the commercialization of medical devices for managing and treating certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.